Premium
The activation on serotonin 2B receptor (5‐HT2BR) is essential for osteoclastogenesis
Author(s) -
Huang YiChieh,
Lin ShiuanYea,
Lu TzongShi,
Huang Bin,
Lin ChihLung,
Fu YawSyan
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.1014.9
Subject(s) - osteoclast , osteoporosis , rankl , agonist , bone remodeling , serotonin , medicine , endocrinology , receptor , pharmacology , chemistry , activator (genetics)
Osteoporosis is the common diseases in elderly people, especially menopausal women. Excessive osteoclastogenesis is one of the main reasons to cause osteoporosis. Recent clinical researches indicated that the patients’ long‐term use of Selective Serotonin Reuptake Inhibitor (SSRI) as anti‐depression drugs usually with higher risk to suffer osteoporosis, and that indicated serotonin (5‐HT) may involve in the regulation of bone metabolism. Some previous reports showed that different types of 5‐HT receptors are expressed in both osteoblasts and osteoclasts. This study was focus on the effects of 5‐HT2BR in osteoclastogenesis. Using RANKL induced osteoclast formation by RAW 264.7 cells as the model, our data showed a positive correlation between the osteoclastogenesis with 5‐HT and 5‐HT2BR agonist treatment and that decrease SirT1 expression. Conversely, treatment with specific 5‐HT2BR antagonist significantly reduced the osteoclast numbers and increase SirT1 expression, and treatment with SirT1 agonist significantly reduced the osteoclasts. In conclusion, our study suggested that 5‐HT2BR play an essential role in osteoclastogenesis and SirT1 may be involved in regulating osteoporosis. Our observations might also provide another direction of prophylaxis and therapy for osteoporosis. Support or Funding Information KMU‐O105001, KMU‐TP104E34, KMU‐TP104E13